SG11201909418WA - Small molecule inhibitors of bcl-2-associated death promoter (bad) phosphorylation - Google Patents
Small molecule inhibitors of bcl-2-associated death promoter (bad) phosphorylationInfo
- Publication number
- SG11201909418WA SG11201909418WA SG11201909418WA SG11201909418WA SG 11201909418W A SG11201909418W A SG 11201909418WA SG 11201909418W A SG11201909418W A SG 11201909418WA SG 11201909418W A SG11201909418W A SG 11201909418WA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- mysore
- university
- singapore
- bangalore
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1706162.3A GB201706162D0 (en) | 2017-04-19 | 2017-04-19 | Compounds |
PCT/SG2018/050194 WO2018194520A1 (en) | 2017-04-19 | 2018-04-18 | Small molecule inhibitors of bcl-2-associated death promoter (bad) phosphorylation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909418WA true SG11201909418WA (en) | 2019-11-28 |
Family
ID=58744515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909418W SG11201909418WA (en) | 2017-04-19 | 2018-04-18 | Small molecule inhibitors of bcl-2-associated death promoter (bad) phosphorylation |
Country Status (12)
Country | Link |
---|---|
US (1) | US11292773B2 (zh) |
EP (1) | EP3612518A4 (zh) |
JP (1) | JP7423010B2 (zh) |
KR (1) | KR20200029384A (zh) |
CN (1) | CN110719906B (zh) |
AU (1) | AU2018256285B2 (zh) |
BR (1) | BR112019022015A2 (zh) |
CA (1) | CA3060939A1 (zh) |
GB (1) | GB201706162D0 (zh) |
IL (1) | IL270078B (zh) |
SG (1) | SG11201909418WA (zh) |
WO (1) | WO2018194520A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201706162D0 (en) * | 2017-04-19 | 2017-05-31 | Nat Univ Singapore | Compounds |
CN112481298A (zh) * | 2020-11-11 | 2021-03-12 | 清华-伯克利深圳学院筹备办公室 | 重组质粒及其应用 |
CN115340527B (zh) * | 2021-05-13 | 2023-09-15 | 成都先导药物开发股份有限公司 | 一种bcl-xl抑制剂及其制备方法和用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002518493A (ja) | 1998-06-25 | 2002-06-25 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | 3−アリール−ベンゾフラノンの製造方法 |
US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
US8252832B2 (en) * | 2007-12-14 | 2012-08-28 | Novartis Ag | Kinesin inhibitors as cancer therapeutics |
WO2010052448A2 (en) | 2008-11-05 | 2010-05-14 | Ucb Pharma S.A. | Fused pyrazine derivatives as kinase inhibitors |
US8916705B2 (en) * | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
JP2017128541A (ja) | 2016-01-21 | 2017-07-27 | 学校法人東京女子医科大学 | アポトーシス誘導剤 |
GB201706162D0 (en) * | 2017-04-19 | 2017-05-31 | Nat Univ Singapore | Compounds |
-
2017
- 2017-04-19 GB GBGB1706162.3A patent/GB201706162D0/en not_active Ceased
-
2018
- 2018-04-18 CN CN201880026001.XA patent/CN110719906B/zh active Active
- 2018-04-18 WO PCT/SG2018/050194 patent/WO2018194520A1/en unknown
- 2018-04-18 EP EP18787822.8A patent/EP3612518A4/en active Pending
- 2018-04-18 IL IL270078A patent/IL270078B/en unknown
- 2018-04-18 AU AU2018256285A patent/AU2018256285B2/en active Active
- 2018-04-18 BR BR112019022015-1A patent/BR112019022015A2/pt unknown
- 2018-04-18 JP JP2020507978A patent/JP7423010B2/ja active Active
- 2018-04-18 SG SG11201909418W patent/SG11201909418WA/en unknown
- 2018-04-18 CA CA3060939A patent/CA3060939A1/en active Pending
- 2018-04-18 US US16/605,630 patent/US11292773B2/en active Active
- 2018-04-18 KR KR1020197034039A patent/KR20200029384A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP3612518A4 (en) | 2020-11-25 |
AU2018256285A1 (en) | 2019-11-07 |
RU2019135562A (ru) | 2021-05-19 |
IL270078B (en) | 2022-09-01 |
CN110719906A (zh) | 2020-01-21 |
JP7423010B2 (ja) | 2024-01-29 |
AU2018256285B2 (en) | 2022-08-04 |
WO2018194520A1 (en) | 2018-10-25 |
CN110719906B (zh) | 2023-07-28 |
EP3612518A1 (en) | 2020-02-26 |
GB201706162D0 (en) | 2017-05-31 |
IL270078A (zh) | 2019-12-31 |
CA3060939A1 (en) | 2018-10-25 |
JP2020517745A (ja) | 2020-06-18 |
US20200131139A1 (en) | 2020-04-30 |
WO2018194520A9 (en) | 2019-10-17 |
US11292773B2 (en) | 2022-04-05 |
KR20200029384A (ko) | 2020-03-18 |
BR112019022015A2 (pt) | 2020-05-12 |
RU2019135562A3 (zh) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806700RA (en) | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | |
SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201901506VA (en) | Distributed systems for the efficient production and use of microbe-based compositions | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201811643TA (en) | Compounds and methods for modulating rna function | |
SG11201811074RA (en) | Nant cancer vaccine | |
SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
SG11201903456WA (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
SG11201806282XA (en) | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies | |
SG11201909418WA (en) | Small molecule inhibitors of bcl-2-associated death promoter (bad) phosphorylation | |
SG11201909057YA (en) | Compact wideband high gain circularly polarized antenna | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201909606RA (en) | Probiotic molecules for reducing pathogen virulence | |
SG11201408163VA (en) | Modified fibronectin fragments or variants and uses thereof | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
SG11201806945SA (en) | Cancer epigenetic profiling | |
SG11201909701PA (en) | Iron ore pellets |